0 9 Detection detection NN 10 12 of of IN 13 26 intracellular intracellular JJ 27 41 phosphorylated phosphorylate VBN 42 48 STAT-1 stat-1 NN 49 51 by by IN 52 56 flow flow NN 57 66 cytometry cytometry NN 66 67 . . . 69 71 We we PRP 72 76 have have VBP 77 84 applied apply VBN 85 89 flow flow NN 90 99 cytometry cytometry NN 100 102 to to TO 103 106 the the DT 107 120 investigation investigation NN 121 123 of of IN 124 140 interferon-gamma interferon-gamma NN 141 151 activation activation NN 152 154 of of IN 155 160 human human JJ 161 170 monocytes monocyte NNS 170 171 . . . 172 176 This this DT 177 185 approach approach NN 186 190 uses use VBZ 191 201 monoclonal monoclonal JJ 202 212 antibodies antibody NNS 213 217 that that WDT 218 229 distinguish distinguish VBP 230 237 between between IN 238 241 the the DT 242 248 native native JJ 249 252 and and CC 253 267 phosphorylated phosphorylated JJ 268 273 forms form NNS 274 276 of of IN 277 283 STAT-1 stat-1 NN 283 284 . . . 285 287 It it PRP 288 295 enables enable VBZ 296 301 rapid rapid JJ 302 305 and and CC 306 318 quantitative quantitative JJ 319 329 assessment assessment NN 330 332 of of IN 333 339 STAT-1 stat-1 NN 340 355 phosphorylation phosphorylation NN 356 358 on on IN 359 360 a a DT 361 369 discrete discrete JJ 370 374 cell cell NN 375 380 basis basis NN 381 384 and and CC 385 387 is be VBZ 388 392 both both DT 393 397 more more RBR 398 407 sensitive sensitive JJ 408 411 and and CC 412 416 less less JJR 417 421 time time NN 422 431 consuming consume VBG 432 436 than than IN 437 451 immunoblotting immunoblotting NN 451 452 . . . 453 464 Furthermore furthermore RB 464 465 , , , 466 468 it it PRP 469 475 allows allow VBZ 476 479 for for IN 480 494 discrimination discrimination NN 495 502 between between IN 503 504 a a DT 505 512 mixture mixture NN 513 515 of of IN 516 521 cells cell NNS 522 526 that that WDT 527 533 differ differ VBP 534 536 in in IN 537 542 their their PRP$ 543 551 response response NN 552 554 to to TO 555 571 interferon-gamma interferon-gamma NN 571 572 . . . 573 577 This this DT 578 586 approach approach NN 587 593 should should MD 594 599 allow allow VB 600 603 for for IN 604 607 the the DT 608 618 evaluation evaluation NN 619 621 of of IN 622 631 different different JJ 632 645 intracellular intracellular JJ 646 655 signaling signaling NN 656 664 pathways pathway NNS 665 670 using use VBG 671 672 a a DT 673 684 combination combination NN 685 687 of of IN 688 698 monoclonal monoclonal JJ 699 707 reagents reagent NNS 708 712 that that WDT 713 716 are be VBP 717 725 specific specific JJ 726 729 for for IN 730 736 native native JJ 737 740 and and CC 741 751 activation activation NN 752 760 modified modified JJ 761 769 proteins protein NNS 769 770 . . . 771 782 Application application NN 783 785 of of IN 786 790 this this DT 791 795 form form NN 796 798 of of IN 799 806 testing testing NN 807 813 should should MD 814 819 prove prove VB 820 828 valuable valuable JJ 829 831 in in IN 832 841 screening screen VBG 842 845 for for IN 846 855 signaling signal VBG 856 863 defects defect NNS 864 866 in in IN 867 875 selected select VBN 876 884 patients patient NNS 885 889 with with IN 890 899 recurrent recurrent JJ 900 910 infections infection NNS 910 911 . . . 912 914 In in IN 915 923 addition addition NN 923 924 , , , 925 929 this this DT 930 939 technique technique NN 940 946 should should MD 947 953 permit permit VB 954 964 dissection dissection NN 965 967 of of IN 968 969 a a DT 970 974 full full JJ 975 980 range range NN 981 983 of of IN 984 992 cellular cellular JJ 993 1002 signaling signaling NN 1003 1011 pathways pathway NNS 1012 1014 at at IN 1015 1018 the the DT 1019 1026 protein protein NN 1027 1032 level level NN 1032 1033 . . .